NVO vs. TSM: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NVO and TSM, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both NVO and TSM are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | NVO | TSM |
|---|---|---|
| Company Name | Novo Nordisk A/S | Taiwan Semiconductor Manufacturing Company Limited |
| Country | Denmark | Taiwan |
| GICS Sector | Health Care | Information Technology |
| GICS Industry | Pharmaceuticals | Semiconductors & Semiconductor Equipment |
| Market Capitalization | 216.69 billion USD | 1,470.04 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | April 30, 1981 | October 9, 1997 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of NVO and TSM by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NVO | TSM |
|---|---|---|
| 5-Day Price Return | 5.55% | -3.05% |
| 13-Week Price Return | -10.49% | 21.19% |
| 26-Week Price Return | -29.53% | 49.43% |
| 52-Week Price Return | -59.81% | 17.52% |
| Month-to-Date Return | -1.55% | -4.67% |
| Year-to-Date Return | -50.17% | 33.02% |
| 10-Day Avg. Volume | 8.31M | 31.79M |
| 3-Month Avg. Volume | 7.13M | 33.56M |
| 3-Month Volatility | 44.27% | 25.73% |
| Beta | 1.58 | 1.29 |
Profitability
Return on Equity (TTM)
NVO
66.95%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
NVO’s Return on Equity of 66.95% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
TSM
34.44%
Semiconductors & Semiconductor Equipment Industry
- Max
- 49.05%
- Q3
- 22.19%
- Median
- 7.96%
- Q1
- 0.99%
- Min
- -15.65%
In the upper quartile for the Semiconductors & Semiconductor Equipment industry, TSM’s Return on Equity of 34.44% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
NVO
32.88%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
A Net Profit Margin of 32.88% places NVO in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
TSM
43.70%
Semiconductors & Semiconductor Equipment Industry
- Max
- 52.41%
- Q3
- 24.47%
- Median
- 11.88%
- Q1
- 0.60%
- Min
- -25.46%
A Net Profit Margin of 43.70% places TSM in the upper quartile for the Semiconductors & Semiconductor Equipment industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
NVO
42.03%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
An Operating Profit Margin of 42.03% places NVO in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
TSM
49.48%
Semiconductors & Semiconductor Equipment Industry
- Max
- 58.09%
- Q3
- 27.76%
- Median
- 12.14%
- Q1
- 3.29%
- Min
- -32.60%
An Operating Profit Margin of 49.48% places TSM in the upper quartile for the Semiconductors & Semiconductor Equipment industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | NVO | TSM |
|---|---|---|
| Return on Equity (TTM) | 66.95% | 34.44% |
| Return on Assets (TTM) | 21.29% | 22.52% |
| Net Profit Margin (TTM) | 32.88% | 43.70% |
| Operating Profit Margin (TTM) | 42.03% | 49.48% |
| Gross Profit Margin (TTM) | 82.05% | 58.98% |
Financial Strength
Current Ratio (MRQ)
NVO
0.78
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
NVO’s Current Ratio of 0.78 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
TSM
2.69
Semiconductors & Semiconductor Equipment Industry
- Max
- 6.57
- Q3
- 4.28
- Median
- 2.86
- Q1
- 2.22
- Min
- 1.02
TSM’s Current Ratio of 2.69 aligns with the median group of the Semiconductors & Semiconductor Equipment industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
NVO
0.60
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
NVO’s Debt-to-Equity Ratio of 0.60 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TSM
0.19
Semiconductors & Semiconductor Equipment Industry
- Max
- 1.18
- Q3
- 0.48
- Median
- 0.24
- Q1
- 0.01
- Min
- 0.00
TSM’s Debt-to-Equity Ratio of 0.19 is typical for the Semiconductors & Semiconductor Equipment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
NVO
149.07
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
With an Interest Coverage Ratio of 149.07, NVO demonstrates a superior capacity to service its debt, placing it well above the typical range for the Pharmaceuticals industry. This stems from either robust earnings or a conservative debt load.
TSM
8.32
Semiconductors & Semiconductor Equipment Industry
- Max
- 174.00
- Q3
- 81.21
- Median
- 22.37
- Q1
- 6.43
- Min
- -7.80
TSM’s Interest Coverage Ratio of 8.32 is positioned comfortably within the norm for the Semiconductors & Semiconductor Equipment industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | NVO | TSM |
|---|---|---|
| Current Ratio (MRQ) | 0.78 | 2.69 |
| Quick Ratio (MRQ) | 0.57 | 2.47 |
| Debt-to-Equity Ratio (MRQ) | 0.60 | 0.19 |
| Interest Coverage Ratio (TTM) | 149.07 | 8.32 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NVO
3.77%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.77%, NVO offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
TSM
1.19%
Semiconductors & Semiconductor Equipment Industry
- Max
- 3.58%
- Q3
- 1.59%
- Median
- 0.61%
- Q1
- 0.00%
- Min
- 0.00%
TSM’s Dividend Yield of 1.19% is consistent with its peers in the Semiconductors & Semiconductor Equipment industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
NVO
68.98%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
NVO’s Dividend Payout Ratio of 68.98% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TSM
27.78%
Semiconductors & Semiconductor Equipment Industry
- Max
- 211.90%
- Q3
- 88.01%
- Median
- 25.84%
- Q1
- 0.00%
- Min
- 0.00%
TSM’s Dividend Payout Ratio of 27.78% is within the typical range for the Semiconductors & Semiconductor Equipment industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NVO | TSM |
|---|---|---|
| Dividend Yield (TTM) | 3.77% | 1.19% |
| Dividend Payout Ratio (TTM) | 68.98% | 27.78% |
Valuation
Price-to-Earnings Ratio (TTM)
NVO
13.31
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
In the lower quartile for the Pharmaceuticals industry, NVO’s P/E Ratio of 13.31 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
TSM
23.37
Semiconductors & Semiconductor Equipment Industry
- Max
- 95.58
- Q3
- 58.67
- Median
- 34.77
- Q1
- 25.45
- Min
- 12.63
In the lower quartile for the Semiconductors & Semiconductor Equipment industry, TSM’s P/E Ratio of 23.37 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
NVO
4.38
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
NVO’s P/S Ratio of 4.38 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TSM
10.21
Semiconductors & Semiconductor Equipment Industry
- Max
- 18.34
- Q3
- 10.38
- Median
- 5.38
- Q1
- 2.49
- Min
- 0.32
TSM’s P/S Ratio of 10.21 aligns with the market consensus for the Semiconductors & Semiconductor Equipment industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
NVO
6.88
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
NVO’s P/B Ratio of 6.88 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
TSM
6.77
Semiconductors & Semiconductor Equipment Industry
- Max
- 16.22
- Q3
- 8.33
- Median
- 4.39
- Q1
- 1.79
- Min
- 0.30
TSM’s P/B Ratio of 6.77 is within the conventional range for the Semiconductors & Semiconductor Equipment industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | NVO | TSM |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 13.31 | 23.37 |
| Price-to-Sales Ratio (TTM) | 4.38 | 10.21 |
| Price-to-Book Ratio (MRQ) | 6.88 | 6.77 |
| Price-to-Free Cash Flow Ratio (TTM) | 21.18 | 41.71 |